PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed

Advanced or metastatic cervical cancer has a poor prognosis, and the 5-year overall survival is <5% with conventional radiotherapy and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), achieved initial success in advanced solid tumors, while their efficacy and safety...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Weijia Huang, Jiewei Liu, Kai Xu, Huilin Chen, Ce Bian
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-10-01
coleção:	Frontiers in Oncology
Assuntos:	cervical cancer tumor microenvironment PD-1 PD-L1 immune checkpoint inhibitor
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.849352/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!